Breaking AI & Tech News Analyzed

HSBC’s chief executive, Georges Elhedery, told Bloomberg Television at a conference in Hong Kong that the ongoing Iran war is undermining global economic confidence. He warned that the conflict’s duration could amplify price pressures on commodities such as oil, refined products, fertilisers and metals, extending the impact far beyond the Middle East. Brent crude, which had briefly risen above $100 per barrel, slipped 0.9% to $98.5 per barrel after a U.S. blockade of Iranian ports took effect. Negotiations between the United States and Iran are set to resume in Islamabad, but no agreement was reached in the previous talks. In London, the FTSE 100 edged up 22 points (0.21%) to 10,605, even as Imperial Brands led the losers, citing a “more uncertain geopolitical and macro environment.” The UK recruitment firm PageGroup warned that the Middle East conflict is creating an “increasingly uncertain outlook” for the rest of the year, with salaries lagging behind 2022‑2023 levels across the UK, Europe, the Middle East and Asia. HSBC holds a 31% stake in Saudi Awwal Bank, making it one of the European banks most exposed to the region, which contributes roughly 4% of its pre‑tax profit according to JP Morgan analysts. Nevertheless, Elhedery noted that capital outflows from the Middle East have been “very benign” so far. Since the U.S. and Israel began striking Iran on 28 February, some affluent Middle‑Eastern investors have started exploring relocation to financial hubs such as Singapore and Hong Kong. HSBC chair Brendan Nelson stressed that a peace settlement is essential to restore global energy flows, warning that prolonged disruption would lift inflation and suppress growth. “The longer the disruption continues, the more the indirect effects from higher energy costs will lift inflation and depress growth,” he said at the HSBC Global Investment Summit. Manufacturers reliant on petroleum‑derived synthetic fabrics, such as sportswear maker Castore, reported cost increases of 10‑15% and warned that continued conflict could push those costs onto consumers. Co‑founder Tom Beahon described price volatility as “very difficult to plan,” with daily swings of up to 40%. Logistics are also strained: airlines have reduced flights and vessels remain stranded in the Strait of Hormuz, complicating product shipments. Castore hopes that a resolution in the coming weeks will limit the impact on customers. Virgin Atlantic chief executive Corneel Koster told the Financial Times that jet‑fuel prices have more than doubled since the war began, adding that “some of this disruption to global energy prices will be here to stay.” UK Chancellor Rachel Reeves, speaking at the IMF and World Bank spring meetings, called for coordinated economic action, stating that the Iran conflict must become “a line in the sand” for how the world handles crises and instability.

Euphoria's third season has been a long-awaited return, but unfortunately, it's absolutely not worth the wait. The show's creator, Sam Levinson, has taken a darker and more desperate approach, focusing on the characters' bleak lives and struggles with sex work, drugs, and trauma.The season picks up five years after the end of season two, with recovering addict Rue (Zendaya) drawn into the world of drug dealer Laurie (Martha Kelly). Her life as a mule between Mexico and the US is depicted in gritty and intense cinematic sequences, drawing on westerns and blaxploitation.Meanwhile, Cassie (Sydney Sweeney) is on the cusp of trad wifedom with toxic jock Nate (Jacob Elordi), but their relationship is marred by Nate's crumbling business and Cassie's OnlyFans content. The show's handling of her cam girl ambitions feels bafflingly dated and voyeuristic.The performances are mostly good, with standout performances from Zendaya, Sweeney, and Adewale Akinnuoye-Agbaje. However, the show's grim and humorless tone makes it feel like a chore to watch.Levinson's approach to exploring the devastating impact of synthetic opioids on ordinary Americans feels heavy-handed and desperate. The show's focus on brainrot bimbo-ism and male perversion also detracts from its once unapologetically queer heart.Overall, Euphoria season three is a disappointing and grubby addition to the series, feeling like a contractual obligation rather than a passion project.

Recent CDC data reveal a dramatic 1,200% increase in kratom‑related poisonings across the United States over the last ten years, with the most pronounced surge recorded in 2025. Researchers link this rise to the growing presence of 7‑hydroxymitragynine (7‑OH), a synthetically produced compound that mimics kratom’s effects but carries opioid‑like risks. Walter Prozialeck, pharmacology professor at Midwestern University, said the trend was expected, noting that the synthetic alkaloid has entered the market through energy drinks and other products since 2024. Christopher McCurdy of the University of Florida warned that marketing 7‑OH as “enhanced kratom” blurs the line for consumers, turning poison‑control calls into a conflated metric for both natural and synthetic products. By contrast, natural kratom (Mitragyna speciosa)—a Southeast Asian plant used for centuries as a pain reliever—has demonstrated a relatively favorable safety profile in animal and human studies. A 2018 statement from then‑HHS Secretary Brett Giroir rejected the DEA’s push to schedule kratom as a Schedule I substance, citing insufficient evidence of harm. Despite the scientific distinction, several states have moved to implement or propose blanket bans on all kratom products, prompting concern from clinicians and patient advocates. A recent user survey indicated that about 50% of respondents rely on kratom for chronic pain, while roughly 40% use it during addiction recovery. Personal testimonies underscore the plant’s therapeutic role. Jeff Maslan, a 68‑year‑old Californian with severe osteoarthritis, credits kratom with easing opioid withdrawal after multiple surgeries. Similarly, “Steven,” a disabled California resident, describes how kratom eliminated unbearable oxycodone withdrawal symptoms without producing the euphoric “warm fuzzy” feeling typical of opioids. Researchers emphasize that 7‑OH carries genuine opioid hazards, including addiction, severe withdrawal, and respiratory depression that can lead to fatal overdose. In animal models, 7‑OH demonstrated the same respiratory‑depression risk as classic opioids, whereas kratom’s primary alkaloid did not. Prozialeck and colleagues explain that kratom’s pharmacology is more nuanced: it partially activates opioid receptors while also engaging adrenergic and serotonin pathways, resembling a hybrid of a weak opioid and an SNRI‑type antidepressant. This multimodal action likely accounts for its lower euphoric potential and the reported boost in energy among users. Nevertheless, experts caution that kratom is not without risk. Fatal poisonings often involve co‑ingestion of potent opioids such as fentanyl, suggesting that some users may cycle between kratom and stronger substances, raising overdose danger due to reduced opioid tolerance. Additionally, heavy‑metal contamination has been detected in certain kratom batches, though the source—soil, processing, or storage—remains unclear. Given these complexities, the consensus among scholars like Austin Zamarripa (Johns Hopkins) is that natural kratom should remain accessible, while concentrated 7‑OH products merit stricter regulation. “These products may offer meaningful benefits to some individuals, and those benefits could be lost if access is restricted too broadly,” Zamarripa said, urging a differentiated policy approach. As the debate unfolds, patients like Steven worry that a sweeping ban would ignore the nuanced safety profile of the plant. “There’s corn on the cob, there’s high‑fructose corn syrup, there’s whiskey— all derived from corn but fundamentally different,” he remarked, highlighting the need for targeted, evidence‑based regulation rather than a one‑size‑fits‑all prohibition.

Bill Ackman's Pershing Square has unveiled a €55.75 bn cash‑and‑shares bid to acquire Universal Music Group (UMG), valuing the label at €30.40 per share – a 78% premium over the previous close of €17.10. The proposal translates to roughly $64.31 bn, positioning it as one of the largest recent takeovers in the entertainment sector. The offer is tied to a strategic plan to relocate UMG’s primary listing from Amsterdam to New York. A U.S. listing would broaden the investor base, potentially attracting index funds and enhancing liquidity, which Ackman argues could lift earnings and drive a higher market valuation. In a letter to UMG’s board, Ackman praised chairman‑CEO Lucian Grainge while criticizing what he described as an “underutilized balance sheet” and the company’s €2.7 bn investment in Spotify Technology. He suggested that a refreshed governance structure – including former Hollywood super‑agent Michael Ovitz as board chair and two Pershing Square directors – would better position the label for future growth. Market reaction was immediate: UMG shares jumped 13% on the news, while Bollore Group’s stock rose 5% and Vivendi’s shares climbed over 10%. Pershing Square currently holds a 4.7% stake in UMG, making it the fourth‑largest shareholder. Key shareholders whose support is essential include Bollore Group (18.5% stake), Vivendi (13.4%), and China’s Tencent. Notably, the Bollore family controls about 80% of UMG’s voting rights, giving it decisive influence over any transaction. Industry analysts point to several headwinds that have pressured UMG’s share price, which has fallen nearly one‑third since its 2021 IPO. Streaming growth is decelerating, and concerns about AI‑generated music – from copyright disputes to fully synthetic songs – are reshaping the competitive landscape. A recent survey found that 97% of listeners can differentiate between AI‑created tracks and human‑composed music. Despite these challenges, global music revenues continue to rise year over year, prompting major labels such as Sony and Warner Music to double‑down on streaming partnerships with platforms like Spotify, Amazon, Apple and Deezer. Under the proposed structure, Pershing’s SPARC Holdings would merge with UMG, creating a Nevada‑incorporated entity listed on the New York Stock Exchange. If approved, the deal could set a precedent for how legacy entertainment firms adapt to evolving technology and investor expectations.

The peptide-testing industry has seen a significant surge in demand, with laboratories testing thousands of unregulated substances claiming to support weight-loss and wellness. This growth is largely driven by the injectable peptide craze, with experts warning about the lack of reliable safety data and quality control.Peptides are short chains of amino acids, which can be found naturally in the body or made synthetically in laboratories. They include active ingredients in prescription weight-loss drugs, such as Wegovy, as well as experimental compounds pushed online by the booming biohacking and anti-ageing industries.Laboratories, such as Finnrick in Texas, have reported a substantial increase in testing requests, with around 60,000 samples processed annually, including roughly 2,000 orders from the UK since 2024. About a third of the products analysed failed basic quality checks, with issues including incorrect identity, purity, and quantity.Experts, including Dr. Luke Turnock and Peter Magic, have highlighted the risks associated with these unregulated substances, including potential long-term harms such as increased cancer risk and damage to organs. The large profit margins have also drawn nefarious actors into the supply chain.The UK is a significant market for peptides, with 2,000 testing orders since 2024, tied with Canada for third place globally. The Royal Pharmaceutical Society's Prof Amira Guirguis emphasized the need for oversight, traceability, and quality assurance in the peptide market.

Peptides are short chains of amino acids that naturally occur in the body, acting as hormones such as insulin, oxytocin and vasopressin, or as fragments released during protein digestion.In recent years, a wave of interest has turned these molecules into purported therapeutic agents for everything from weight loss to anti‑ageing and tissue repair. Prescription drugs like semaglutide (Wegovy) and tirzepatide (Mounjaro) are synthetic peptides that have undergone rigorous clinical testing and are approved for specific medical uses.However, a large portion of the market consists of unregulated, experimental peptides sold for self‑administration. These products often bypass the strict approval processes required for medicines, raising serious safety concerns.Who is using these products? Initially confined to a niche of powerlifters and bodybuilders in the 2010s, the audience has expanded dramatically. Influential figures such as podcaster Joe Rogan have promoted combinations like the “Wolverine stack” (BPC‑157 and TB‑500) for injury recovery, while other compounds—CJC‑1295, MK‑677, ipamorelin, and GHK‑Cu—are marketed for muscle growth and anti‑ageing. Social media platforms are now flooded with instructions on purchasing and injecting these substances.Scientific backing is scant. Reviews of the literature reveal that most experimental peptides have only been tested in animal or cell models. For example, BPC‑157 shows promise for tendon and muscle repair in pre‑clinical studies, but no randomized human trials have validated these effects. Similarly, TB‑4 and its synthetic analogue TB‑500 have demonstrated limited blood‑vessel formation in laboratory settings, yet human data are absent and both are listed as prohibited substances by the World Anti‑Doping Agency.Researchers also highlight a critical knowledge gap: dosage, frequency and treatment duration remain undefined, making self‑administration a gamble.Legal landscape in the UK is clear that peptides not classified as medicines fall outside the Medicines and Healthcare products Regulatory Agency’s (MHRA) remit. If a seller makes medicinal claims, the product must hold a marketing authorisation under the Human Medicines Regulations 2012. The MHRA warns that labeling items as “research use only” does not shield vendors from enforcement when evidence shows the products are intended for human consumption.Health risks are multi‑fold. Experts caution that benefits observed in animal studies do not guarantee safety in humans. Contamination with harmful impurities or bacterial endotoxins can trigger severe reactions, including septic shock. Injecting excess natural peptides may disrupt the body’s tightly regulated hormonal balance, potentially affecting multiple physiological pathways.There is also theoretical concern that augmenting peptide levels could accelerate tumour growth, as some cancers over‑express certain peptide pathways. While no direct cases have been documented, the possibility underscores the need for caution.Additional dangers include improper injection techniques (e.g., air embolism), unknown interactions with existing medications, and the lack of systematic monitoring of long‑term effects. As one researcher put it, “If something goes wrong, users may never notice until irreversible damage has occurred.”

The UK medicines regulator has opened an inquiry into a growing number of clinics that sell injectable peptides while promoting them as cures for everything from ageing to injury recovery. The investigation, disclosed by the Guardian, focuses on whether these businesses are breaching the Human Medicines Regulations 2012 by making unauthorised medicinal claims. Interest in peptide‑based treatments has surged in recent years, driven by social‑media influencers, some healthcare professionals, and direct‑to‑consumer marketers. Yet the scientific foundation for most of these claims is weak, with the bulk of research confined to animal models or cell‑culture studies. According to an MHRA spokesperson, any clinic that advertises a peptide as having therapeutic benefits must treat the product as a medicine, which triggers a comprehensive regulatory framework. "If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation," the agency warned, adding that it will act against any identified breaches. Guardian reporters identified several high‑ranking Google search results that list peptides such as Cortexin (promoted for neuroprotection), BPC‑157 (claimed to aid tissue repair), and Thymosin Alpha (advertised to boost immunity). After being contacted, one clinic removed the statements from its website. Another clinic, while acknowledging the limited human evidence, continued to market seven specific peptides, providing price lists (£350 per month for a single peptide, £450 for two) and offering delivery via vials, syringes, or pre‑filled pens for an additional fee. During a free consultation, a clinician highlighted the experimental nature of the products, noting the absence of large‑scale, randomised clinical trials and recommending a break of four to eight weeks between treatment cycles to mitigate unknown risks. The clinician suggested BPC‑157 for post‑exercise recovery, describing it as a facilitator of cellular repair and blood flow, but warned against its use in smokers or individuals with a family history of cancer due to potential angiogenic effects. The second peptide discussed was MOTS‑C, portrayed as a mitochondrial enhancer that could improve stress resilience, lower insulin resistance, and reduce visceral fat by boosting cellular energy production (ATP). The MHRA confirmed it is reviewing whether the clinician’s statements constitute medicinal claims. The clinic defended its approach, emphasizing that it clearly informs clients that the peptides are not licensed medicines and that the evidence base is largely pre‑clinical. In a broader statement, Lynda Scammell, head of borderline products at the MHRA, explained that peptide products may be marketed as cosmetics, supplements, or medicines, and each case is assessed on its intended use, pharmacological effect, and supporting evidence. She added, "We disregard claims that products are for ‘research purposes’ if it is clear that such claims are being used as an attempt to avoid medicines regulations." Peptides are short chains of amino acids, some of which occur naturally (e.g., insulin). While synthetic peptide analogues like semaglutide and tirzepatide have secured approval for weight‑loss treatments, many of the compounds promoted by these clinics remain experimental and lack the rigorous safety and efficacy testing required for medicinal products.

French authorities detained European Parliament member Rima Hassan on Thursday, accusing her of "apology for terrorism" after a social‑media post referenced Kozo Okamoto, a participant in the 1972 Ben Gurion Airport attack. The detention, reported by Le Parisien, marks a rare instance where a sitting MEP’s parliamentary immunity appears to have been set aside. According to the newspaper, Hassan had already removed the contentious post from X, but the investigation continued. Police also reported finding a small quantity of synthetic drugs in her possession during the arrest. Jean‑Luc Mélenchon, founder of the left‑wing La France Insoumise (LFI) party, condemned the move on X, stating, "There is no longer parliamentary immunity in France. Intolerable." He and other LFI colleagues argue the action is designed to silence supporters of Palestine. LFI parliamentarians Sophia Chikirou and Mathilde Panot echoed the criticism, accusing the French police and justice system of being weaponised against activists. Panot warned that President Emmanuel Macron’s France is witnessing a "new level" of criminalisation of political opponents. The controversy follows Hassan’s recent denial of entry to Canada, which she described as censorship, and a prior alert by far‑right National Rally politician Matthias Renault to Paris prosecutors about the same X post. Renault welcomed the detention, calling it "the beginning of the end of impunity for the LFI MP." Hassan, a 33‑year‑old French‑Palestinian lawyer elected to the European Parliament in 2024, is a vocal critic of Israel’s war in Gaza and participated in a Gaza‑bound flotilla intercepted by Israeli forces in October 2025. Her advocacy has repeatedly drawn ire from pro‑Israel groups across Europe. While Hassan and her legal team have not responded to Reuters’ requests for comment, the incident raises broader questions about the balance between anti‑terrorism legislation and political freedoms within the EU, especially as debates over Palestine intensify across the continent.

Kenyan marathon runner Albert Korir, the 2021 New York City Marathon champion, has been handed a five-year doping ban by the Athletics Integrity Unit (AIU). Korir admitted to using a banned performance-enhancing drug, specifically the synthetic form of erythropoietin (EPO), which stimulates red blood cell production.The ban, which runs from January 8 until January 7, 2031, was reduced from six years due to Korir's early admission and acceptance of the sanction. The 32-year-old athlete tested positive during out-of-competition tests in Kenya in October.Korir has had a notable career, winning the 2021 New York marathon in a time of 2 hours, 8 minutes, and 22 seconds. He also came third in the 2023 New York marathon with a personal best time of 2:06:57. Additionally, he won the Ottawa Marathon in 2019 and 2025.This sanction comes as part of Kenya's ongoing efforts to clean up its image in athletics, following a string of doping scandals. Over 140 Kenyan runners, mainly long-distance athletes, have been sanctioned for drugs offences since the 2016 Rio de Janeiro Olympics. Recently, Kenya handed out its first lifetime ban to marathon runner Beatrice Toroitich and a six-year ban to 10km record holder Rhonex Kipruto in June 2024.